CLRB241220P2500
- 2.45
- 0.000.00%
Cellectar BioSciences Newsroom
Cellectar Biosciences Cut to Perform From Outperform by Oppenheimer
Cellectar Biosciences Analyst Ratings
Oppenheimer Downgrades Cellectar BioSciences(CLRB.US) to Hold Rating
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $7
Positive Buy Rating on Cellectar Biosciences Driven by Promising Iopofosine-131 Results and Strategic Advancements
Cellectar Biosciences Is Maintained at Outperform by Oppenheimer
Oppenheimer Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Cuts Target Price to $12
Cellectar Biosciences Analyst Ratings
Oppenheimer Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $14
Oppenheimer Keeps Their Buy Rating on Cellectar Biosciences (CLRB)
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $7
Oppenheimer Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $14
Oppenheimer Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Raises Target Price to $14
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $7
Buy Rating Affirmed for Cellectar Biosciences on Strong Clinical Results and Improved Financial Outlook
Buy Rating on Cellectar Biosciences Backed by Strong Clinical Data and Promising Drug Pipeline
Buy Rating on Cellectar Biosciences Backed by Promising Drug Candidate and Solid Financials
Analysts Conflicted on These Healthcare Names: Cellectar Biosciences (CLRB), MiMedx Group (MDXG) and Marinus (MRNS)
Cellectar Biosciences Analyst Ratings
Buy Rating Affirmed for Cellectar Biosciences on Strong Clinical Results and Acquisition Potential